Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANThEON: Gemcitabine + Nab-Paclitaxel vs mFOLFIRINOX in Advanced Pancreatic Cancer
NCT06897644Phase 3Recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Mar 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Gruppo Oncologico Nord Ovest. Started Mar 2025; status: recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06897644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897644.